Table 1.
Baseline characteristics of patient population.
| n (N = 87) | |||
|---|---|---|---|
| Demographic information | Sex (female) | 87 | 55 (63.2%) |
| Age at diagnosis (years) | 87 | 61.1 ± 14.0 | |
| BMI > 30 kg/m2 | 69 | 22 (31.9%) | |
| Medical history | Previous PEA | 87 | 4 (4.6%) |
| Systemic hypertension | 85 | 29 (34.1%) | |
| Diabetes mellitus | 86 | 8 (9.3%) | |
| CAD | 85 | 3 (3.5%) | |
| Clinical parameters | WHO FC III/IV | 87 | 52 (59.8%) |
| 6MWD (m) | 74 | 380 ± 142 | |
| NTproBNP (pg/mL) * | 81 | 344 [108–1788] | |
| Pulmonary hemodynamics | mRAP (mmHg) | 79 | 8.8 ± 5.6 |
| mPAP (mmHg) | 86 | 38.9 ± 10.0 | |
| PAWP (mmHg) | 83 | 10.7 ± 5.0 | |
| CO (L/Min) | 82 | 5.2 ± 1.9 | |
| PVR (WU) | 81 | 6.4 ± 3.6 | |
| Anticoagulation type | DOAC | 87 | 24 (27.6%) |
| VKA | 63 (72.4%) | ||
| PH-targeted medical therapy after the MDT | No | 87 | 7 (8.0%) |
| Mono | 25 (28.7%) | ||
| Dual | 54 (62.1%) | ||
| Triple | 1 (1.1%) | ||
| ERA | 87 | 65 (74.7%) | |
| Riociguat | 87 | 39 (44.8%) | |
| PDE5i | 87 | 31 (35.6%) | |
| Oral prostanoid | 87 | 1 (1.1%) |
BMI = Body Mass Index; BPA = Balloon Pulmonary Angioplasty; CAD = Coronary Artery Disease; CO = Cardiac Output; DOAC = Direct Oral Anticoagulant; ERA = Endothelin Receptor Antagonist; IQR = Interquartile Range; MDT = multidisciplinary team; mPAP = mean Pulmonary Arterial Pressure; mRAP = mean Right Atrial Pressure; n = non-missing; NTproBNP = N-terminal Fragment of Pro-Brain Natriuretic Peptide; PEA = Pulmonary Endarterectomy; PAWP = Pulmonary Arterial Wedge Pressure; PDE5i = Phosphodiesterase-5 Inhibitor; PH = Pulmonary Hypertension; PVR = Pulmonary Vascular Resistance; WHO FC = World Health Organization Functional Class; VKA = Vita-min K Antagonist; 6MWD = 6-min walking distance Note: Data are given as mean ± standard deviation or n (%) or * median [IQR].